Emerging evidence indicates that Fascin-1 (FSCN1) may possess a causal role in the development of several types of cancers and serves as a novel biomarker of aggressiveness in certain carcinomas. However, the regulatory mechanism of FSCN1 in triple-negative breast cancer (TNBC) cell invasion and migration is still largely unknown. In our study, we observed that the FSCN1 expression rates were significantly higher in invasive ductal carcinoma, compared with both usual ductal hyperplasia and ductal carcinoma in situ. FSCN1 expression was significantly higher in cases of TNBC compared with the non-TNBC subtype. Overexpression of FSCN1 promoted TNBC cell migration and invasion. Epidermal growth factor induced the expression of FSCN1 through activation of MAPK, which subsequently promoted cell migration and invasion. A significant decrease in FSCN1 expression following the cotreatment of FSCN1 siRNA and Gefitinib, compared with the separate treatment of FSCN1 siRNA or Gefitinib. Furthermore, we found that there was a significant association between FSCN1 expression and poor relapse-free survival and overall survival. Therefore, we suggest that co-targeting epidermal growth factor receptor and FSCN1 dual biomarker may be used as a novel therapeutic strategy for TNBC.
In the present report, we used immunohistochemical (IHC) analysis to detect FSCN1 expression in a series of paraffin-embedded breast lesion tissue, including that from usual ductal hyperplasia (UDH), ductal carcinoma in situ (DCIS), and invasive ductal carcinoma (IDC), and analyzed the relationship between FSCN1 and TNBC or epidermal growth factor receptor (EGFR). The relationship between FSCN1 expression and clinical pathological features and prognosis were analyzed in patients with IDC. We further described the potential mechanism by which FSCN1 contributes to TNBC cell migration and invasion. In addition, we demonstrated that EGF induced the expression of FSCN1 through MAPK activation, subsequently promoting cell migration and invasion. Furthermore, we found there to be a significant decrease in FSCN1 expression following the co-treatment of FSCN1 siRNA and Gefitinib, compared with the separate treatment of FSCN1 siRNA or Gefitinib.
Results
FSCN1 is expressed in breast tissue specimens and is associated with clinical pathological parameters in patients with IDC. To define the potential role of FSCN1 in the progression of mammary carcinoma, we performed IHC analysis to assess the expression of FSCN1 on 125 UDH, 104 DCIS, and 467 IDC tissue samples (Fig. 1A-D) . As shown in Table 1 , the rates of positive FSCN1 expression in UDH, DCIS and IDC were 6.4% (8/125), 17 .3% (18/104), and 33.0% (154/467), respectively (P < 0.0001). Additionally, we also observed that FSCN1 expression is significantly associated with a number of clinical parameters of IDC patients, including tumor size (P = 0.024), grade (P < 0.0001), stage (P = 0.045), ER-(P < 0.0001), PR-(P < 0.0001) and axillary lymph node metastasis (P = 0.024) ( Table 2 ). Interestingly, we also observed that FSCN1 expression was significantly higher in cases of TNBC (88.6%, 62/70) compared with the non-TNBC subtype (19.2%, 71/370) (P < 0.0001) ( Table 2 ), which is indicative that FSCN1 expression is associated with TNBC.
FSCN1 expression is associated with TNBC. To determine the association between FSCN1 expression and ER, PR, HER2, respectively, we performed an integrative analysis of mRNA expression of clinical data published by The Cancer Genome Atlas (TCGA) database. As shown in Fig. 2 , we found significantly negative correlation between FSCN1 and ER, PR, and HER2 (P < 0.0001), further suggesting that FSCN1 expression is associated with TNBC.
FSCN1 promotes migration and invasion of TNBC in vitro.
In order to further understand the possible role of FSCN1 in TNBC, we next assessed the potential impact of FSCN1 on mammary carcinoma cell migration and invasion in TNBC cells. We performed a preliminary screen for expression levels of FSCN1 in four mammary carcinoma cell lines (contains one of the non-TNBC cell line MCF-7, and three TNBC cell lines MDA-MB-468, MDA-MB-231 and MDA-MB-453) by Real-Time Polymerase Chain Reaction (PCR) (Fig. 3A) . Then, we determined the potential impact of FSCN1 on the phenotype of the TNBC cells MDA-MB-468 and MDA-MB-231 migration and invasion, through manipulation of the expression levels of FSCN1 by transfection of FSCN1 expression plasmids (Fig. 3B ). As shown in Fig. 3 , forced expression of FSCN1 resulted in significantly increased MDA-MB-468 (Fig. 3D ) and MDA-MB-231 (Fig. 3G ) cells migration and invasion compared with control vector. Conversely, depletion of FSCN1 by transfection of FSCN1 siRNA resulted in a significant reduction in cell migration and invasion compared with cells transfected with control oligonucleotides in the MDA-MB-468 and MDA-MB-231 cell lines (Fig. 3C,E,H) . Furthermore, forced expression of FSCN1 resulted in significantly increased non-TNBC MCF-7 cell migration and invasion compared with control vector (Fig. 3B,J) . In comparison, there was no significant reduction of migration and invasion in the MCF-7 cell line which express very low level of FSCN1, compared with cells transfected with control oligonucleotides (Fig. 3C,K) . Taken together, these data indicate that overexpression of FSCN1 dramatically promotes invasiveness of TNBC cells in vitro.
It is notable that FSCN1 expression was able to influence proliferation of MDA-MB-231 cells; however, this was not the case for the MDA-MB-468 cell line (Fig. 3F,I ). In consolidation with these results, a previous report 7 also demonstrated that FSCN1 promoted the migration and invasive ability, but not the proliferation of non-small cell lung cancer. This suggested that FSCN1 has various functional roles in a highly context-dependent manner in different cell lines.
EGF regulates the FSCN1 expression and activates MAPkinase signaling in TNBC. We further investigated the signaling pathway modulated by FSCN1 in the progression of TNBC. EGF has previously been demonstrated to regulate MAPK activation 14 . We and others have also previously reported that both EGF and MAPK enhanced breast cancer cell migration and invasion 15, 16 . Therefore, we further sought to determine whether FSCN1 contributed to EGF-mediated mammary carcinoma cell migration and invasion.
We first demonstrated that mRNA and protein expression levels of FSCN1 in EGF-stimulated TNBC cells were significantly increased. Conversely, the treatment of TNBC cells with EGFR inhibitor Gefitinib 17 , resulted in decreased mRNA and protein expression of FSCN1 in the MDA-MB-468 cell line, but not in the MDA-MB-231 cell line (Fig. 4A,B, Supplementary Figure 1A ,B), suggesting that there is likely to be Gefitinib resistance in TNBC cells. Transfection of FSCN1 siRNA consistently decreased EGF regulated cell migration and invasion (Fig. 4C,D) , indicating that EGF stimulated TNBC cell function modulated by the combinatory functionality of FSCN1.
To further determine whether MAPK was required for FSCN1 mediated TNBC cell migration and invasion, we assessed FSCN1 expression levels by co-treatment cells with EGF and MAPK specific inhibitor U0126. As shown in Fig. 4E ,F, inhibition of MAPK activity was demonstrated to diminish the mRNA and protein expression levels of FSCN1 while EGF promoted that of FSCN1(Supplementary Figure 1C,D) . Moreover, MAPK specific inhibitor U0126 abrogated the enhancement of FSCN1 expression stimulated by the treatment with EGF. It is therefore apparent that EGF/MAPK signaling was utilized to drive invasion and migration consequent to forced expression of FSCN1. 
Group
No.
FSCN1 expression
Negative, n (%) Positive, n (%) Table 1 . The expression of FSCN1 in patients with UDH, DCIS, and IDC. Note: *P < 0.0001.
Importantly, we detected a significant decrease in migration after co-treatment with FSCN1 siRNA and Gefitinib, compared to the single treatment with FSCN1 siRNA and Gefitinib (Fig. 4G,H) , suggesting that combined inhibition of EGFR and FSCN1 may be used as a novel therapeutic strategy for TNBC.
Furthermore, we analyzed the association between EGFR expression and ER, PR, and HER2 using TCGA database. Interestingly, we found a significantly negative correlation between EGFR and ER, PR, and HER2 (P < 0.0001). Consistently, we found there was positive correlation between FSCN1 and EGFR, MAPK1 (P < 0.0001, Fig. 4I ). Thus, we hypothesized that FSCN1 utilizes the EGFR-MAPK signaling pathway to play functionality.
Additionally, we detected the expression of EGFR in IDC using IHC and analyzed its relationship with TNBC. EGFR expression levels were significantly higher in TNBC (78.6%, 55/70) compared with non-TNBC (44.3%, 164/370) (P < 0.0001, Table 3 , Fig. 1E,F) , and FSCN1 expression was significantly higher in EGFR positive IDC cases (51.6%, 126/243) compared with EGFR negative cases (12.5%, 28/224) (P < 0.0001, Table 4 ).
FSCN1 expression is associated with survival of patients with IDC. To assess the potential impact of FSCN1 on patient survival, we analyzed FSCN1 expression in relation to relapse-free survival (RFS) and overall survival (OS) in patients with IDC.
As shown in Fig. 5A ,B, patients whose primary tumors expressing FSCN1 (n = 61) had a mean RFS of 47.5 months (at a 55.7% 5-year RFS rate), whereas patients whose tumors did not express FSCN1 (n = 111) had a mean RFS of 53.2 months (at a 76.6% 5-year RFS rate, P = 0.0073, Fig. 5A ). Patients whose primary tumors expressed FSCN1 (n = 61) had a mean OS of 52.6 months (at a 70.5% 5-year OS rate), whereas patients who did not express FSCN1 (n = 111) had a mean OS of 57.1 months (at a 86.5% 5-year OS rate, P = 0.0089, Fig. 5B ). Taken together, these results suggested that FSCN1 could be used as a potential clinical biomarker for breast cancer.
We further specifically analyzed the survival in TNBC cases. As shown in Fig. 5C ,D, FSCN1 positive patients were associated with worse RFS and OS in our TNBC cases, which was consistent with our finding in the IDC patients. However, no unequivocal association was observed in our 44 TNBC cases (P = 0.1876 and P = 0.1156, respectively). Considering that there were only 6 FSCN1 negative cases in our collection, we further analyzed 91 TNBC patients from 1105 samples of TCGA breast cancer database. TNBC patients were divided into two groups based on median FSCN1 mRNA expression of all patients, and subsequently RFS and OS were further analyzed. As shown in Fig. 5E ,F, we analyzed and found that high expression of FSCN1 was significantly associated with worse 5-year RFS, while there was no unequivocal association was observed between FSCN1 and OS. Taken together, these results suggested that high FSCN1 could be potentially used as a predictor of disease recurrence in patients with TNBC.
Discussion
Reports concerning FSCN1 as a novel therapeutic biomarker for aggressive and metastatic carcinomas are limited [18] [19] [20] [21] . In this study, we observed that the expression levels of FSCN1 were significantly higher in patients with IDC, compared with those in patients with UDH and DCIS. In addition, FSCN1 expression was associated with a number of poor prognostic characteristics in patients with IDC, suggesting that FSCN1 may be linked to the progression of mammary carcinoma. In addition, we also observed that FSCN1 expression was significantly higher in TNBC compared with the non-TNBC subtype, and we verified the potential functional role of FSCN1 expression in the progression of TNBC. Therefore, our findings assist in understanding the functional role of FSCN1 in TNBC progression, and may provide new understanding of the mechanism of neoplastic progression. FSCN1 is expected to possess other functional roles in addition to the findings detailed herein. For example, knockdown or knockout of FSCN1 can lead to a reduction of nodal signal transduction and endoderm formation in zebrafish embryos, in addition, the depletion of FSCN1 disrupts the association between receptors and actin filaments and sequesters the internalized receptors into clathrin-coated vesicles 22 . TNBC is an aggressive subtype associated with poor survival, and unlike patients with the non-TNBC subtype, TNBC is not amenable to hormonal or HER2-targeting therapy [4] [5] [6] . Therefore, the identification of novel treatment strategies for TNBC is important. In this study, we found that FSCN1 expression was significantly higher in TNBC and dramatically promotes invasiveness of TNBC cells in vitro. Then, we sought to identify how FSCN1 promotes TNBC invasion. EGFR, is initially expressed on the plasma membrane in an inactive form, and becomes activated through certain kinases and/or after binding to its specific ligands [23] [24] [25] [26] . It is known that EGFR activation occurs via kinases and/or transactivation through binding to specific ligands, including EGF 27 . EGFR is abnormally expressed and activated in many cancer cells, and initiates signal transduction cascades that promote cell division, migration and angiogenesis 28 . We and others have shown that EGFR is highly expressed in TNBC and is a potential therapeutic target, and is associated with poor prognosis [29] [30] [31] . At present, EGFR inhibitor Gefitinib and anti-EGFR monoclonal antibody cetuximab, have shown little efficacy in the majority of clinical studies regarding TNBC [32] [33] [34] [35] . Drug resistance to EGFR targeted therapy is caused by a variety of reasons, including MET amplification and overexpression 36 and nuclear EGFR 37 . Therefore, for the identification of therapeutic targets that act synergistically with EGFR targeted therapies has potential to improve the survival rate and quality of life of patients with TNBC. Our results showed that the EGFR/MAPK/ FSCN1 signaling pathways promotes TNBC invasion and a greater inhibitory effect on TNBC cells was observed after the co-treatment of FSCN1 siRNA with Gefitinib compared with the separate treatment of FSCN1 siRNA or Gefitinib. We also observed decreased FSCN1 expression and migration ability in MDA-MB-468 cells after treatment with Gefitinib, but these effects were not obvious in MDA-MB-231 cells. And we found that FSCN1 expression in MDA-MB-231 cells was significantly higher than that in MDA-MB-468 cells. Thus, we hypothesized that TNBC cells exhibit resistance to EGFR targeted therapy, part of the mechanism may be that EGFR/MAPK cannot completely regulate FSCN1, and there may be other upstream regulatory mechanisms affecting FSCN1. Taken together, our discovery indicates that co-targeting EGFR and FSCN1 dual biomarker could significantly decrease the abilities of migration and invasion in TNBC.
It should be noted that FSCN1 could be expected to possess a wide range of functions in the progression of breast cancer. The functions of FSCN1 are yet to be fully elucidated. Further studies are therefore required to fully understand the functional roles and interactions of FSCN1 with regard to therapeutics for breast cancer, particularly for TNBC.
Methods and Materials
Patients and specimens. The IHC Analysis. IHC staining of paraffin-embedded tissue sections was carried out using the Envision System (Dako, Glostrup, Denmark) as described previously 13 . The primary antibodies used were as follows: anti-FSCN1 mouse monoclonal antibody (clone 55k-2, diluted at 1:100, Santa Cruz Biotechnology, Santa Cruz, USA); anti-EGFR rabbit polyclonal antibody (clone 1005, diluted at 1:100, Santa Cruz Biotechnology); HercepTest (Dako); ready-to-use anti-ER rabbit monoclonal antibody (clone SP1, Dako); ready-to-use anti-PR mouse monoclonal antibody (clone PR636, Dako).
FISH Analysis. Breast cancer cases with HER2 2+ equivocal results determined by IHC analysis required further detection using FISH. In this study, there were 27 cases of breast cancer with ER-, PR-, and HER2 2+ equivocal status did not undergo FISH, and leads to uncertain classification as TNBC or non-TNBC subtype. FISH analysis was performed on paraffin embedded tissue sections using the PathVysion HER2 DNA Probe Kit (Abbott-Vysis, Des Plaines, Illinois) as described previously 13 . lines. FSCN1 expression is normalized to GAPDH. The data are presented as the mean ± S.E.M. from three independent experiments, each performed in triplicate. *P < 0.01. Under, Western blot was used to analyze the expression levels of FSCN1. Total cellular protein was isolated and subjected to western blot analysis for FSCN1 expression. GAPDH was used as loading control. Bottom, The quantitative result of western blot is shown. (G,H) Transwell assays. Cells were grown and transfected with FSCN1 siRNA or control siRNA for 2 days and treated with 100 ng/mL Gefitinib or vehicle for 45 min. Cells were subsequently subjected to assays. *P < 0.01. I. Correlation analysis of the TCGA Breast Invasive carcinoma database (TCGA, Provisional 2012) using cBioPortal show the association between MAPK1/EGFR and FSCN1 mRNA levels, in addition to ESR1 (ER)/ PGR (PR)/ERBB2 (Her2)/MAPK1 and EGFR mRNA levels. P < 0.0001.
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Database analysis. The gene expression profiling of 825 invasive breast carcinomas (with recorded progression stages) was generated by TCGA database. Among those samples, 299 had no information regarding serous grades. Our analysis was based on the Agilent microarray (TCGA, Nature 2012). The Kaplan-Meier survival curve analyses of 1105 samples (TCGA, Provisional) were carried out using log-rank tests in GraphPad Prism (GraphPad Software). TNBC patients were divided into two groups based on median FSCN1 mRNA expression of all patients, and subsequently RFS and OS were further analyzed.
Statistical analysis. All statistical analyses were performed using SPSS 19.0 software (SPSS Inc, Chicago, IL, USA). Numerical data are expressed as mean ± standard error of the mean from a representative experiment performed in triplicate. Differences/correlations between groups were compared using Pearson's chi-square test for qualitative variables and Student's t-test for continuous variables. Patient RFS and OS rates were analyzed using the Kaplan-Meier method and compared by log-rank analysis. P < 0.05 was considered statistically significant. 
